# C21orf30 (P-18): sc-83529



The Power to Question

#### **BACKGROUND**

The smallest of the human chromosomes, 21 makes up about 1.5% of the human genome. Chromosome 21 contains nearly 300 genes and 47 million base pairs. Down syndrome, also known as trisomy 21, is the disease most commonly associated with chromosome 21. Alzheimer's disease, Jervell and Lange-Nielsen syndrome and amyotrophic lateral sclerosis are also associated with chromosome 21. Translocations are found to occur between chromosome 21 and 8, and chromosome 21 and 12 in certain leukemias. The C21orf30 gene product has been provisionally designated C21orf30 pending further characterization.

# **REFERENCES**

- Tesson, F., et al. 1996. Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. J. Mol. Cell. Cardiol. 28: 2051-2055.
- Tyson, J., et al. 1997. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum. Mol. Genet. 6: 2179-2185
- Müller, S., et al. 2000. Molecular cytogenetic dissection of human chromosomes 3 and 21 evolution. Proc. Natl. Acad. Sci. USA 97: 206-211.
- 4. Mao, R., et al. 2005. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol. 6: R107.
- Robakis, N.K. 2006. The discovery and mapping to chromosome 21 of the Alzheimer's amyloid gene: history revised. J. Alzheimers Dis. 10: 453-455.
- Sun, X., et al. 2006. BACE2, as a novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 20: 1369-1376.
- Aït Yahya-Graison, E., et al. 2007. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 81: 475-491.
- 8. Peterson, L.F., et al. 2007. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 110: 799-805.
- Ryoo, S.R., et al. 2007. DYRK1A-mediated hyperphosphorylation of Tau: a functional link between Down syndrome and Alzheimer's disease. J. Biol. Chem. 282: 34850-34857.

# **CHROMOSOMAL LOCATION**

Genetic locus: C21orf30 (human) mapping to 21q22.3.

# **SOURCE**

C21orf30 (P-18) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within an internal region of C21orf30 of human origin.

### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### **PRODUCT**

Each vial contains 100  $\mu g$  lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-83529 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

# **APPLICATIONS**

C21orf30 (P-18) is recommended for detection of C21orf30 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for C21orf30 siRNA (h): sc-106958, C21orf30 shRNA Plasmid (h): sc-106958-SH and C21orf30 shRNA (h) Lentiviral Particles: sc-106958-V.

Molecular Weight of C21orf30: 26 kDa.

# **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

# **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

**Santa Cruz Biotechnology, Inc.** 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**